For the quarter ending 2025-09-30, TOI made $136,564K in revenue. -$16,504K in net income. Net profit margin of -12.09%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total operating revenue | 136,564 | 119,802 | 98,578 | |
| Direct costs-Health Care Patient Service | 54,572 | 51,150 | - | |
| Direct costs-Dispensary Revenue | 63,072 | 51,086 | - | |
| Direct costs | - | - | 85,323 | |
| Direct costs-Clinical Research Trials And Other Revenue | 0 | 65 | - | |
| Selling, general and administrative expense | 25,251 | 26,907 | 27,872 | |
| Depreciation and amortization | 1,723 | 1,805 | 1,518 | |
| Total operating expenses | 144,618 | 131,013 | 114,942 | |
| Loss from operations | -8,054 | -11,211 | -16,364 | |
| Interest expense, net | 1,920 | 1,870 | 2,118 | |
| Change in fair value of derivative warrant liabilities | 150 | 53 | -552 | |
| Change in fair value of conversion option derivative liabilities | -5,977 | -3,987 | 2,568 | |
| Other, net | -403 | -19 | -117 | |
| Total other non-operating loss | -8,450 | -5,929 | 885 | |
| Loss before provision for income taxes | -16,504 | -17,140 | -15,479 | |
| Income tax benefit | 0 | -131 | - | |
| Net loss | -16,504 | -17,009 | -15,479 | |
| Basic (in dollars per share) | -0.14 | -0.15 | -0.17 | |
| Basic (in shares) | 97,474,797 | 93,203,665 | 74,748,365 | |
| Diluted (in dollars per share) | -0.14 | -0.15 | -0.17 | |
| Diluted (in shares) | 97,474,797 | 93,203,665 | 74,748,365 | |
Oncology Institute, Inc. (TOI)
Oncology Institute, Inc. (TOI)